|Articles|April 1, 2004

April 2004
Volume 10
Issue 4

Verification of a Decision Analytic Model Assumption Using Real-world Practice Data: Implications for the Cost Effectiveness of Cyclo-oxygenase 2 Inhibitors (COX-2s)

Author(s)Robert Valuck, PhD, RPH. Author Reply by Emily R. Cox, PhD, Brenda Motheral, PhD, Doug Mager, BS

Articles in this issue

over 22 years ago

Article

Improving Cancer Screening Adherence: Using the "Teachable Moment" as a Delivery Setting for Educational Interventions

over 22 years ago

Article

Population-Based Hepatitis C Surveillance and Treatment in a National Managed Care Organization

over 22 years ago

Article

Malpractice Prevention, Patient Safety, and Quality of Care: A Critical Linkage

over 22 years ago

Article

Comparing Breast Cancer Case Identification Using HMO Computerized Diagnostic Data and SEER Data

over 22 years ago

Article

Health Plan Policies and Programs for Colorectal Cancer Screening: A National Profile

over 22 years ago

Article

Primary Care Practice and Facility Quality Orientation: Influence on Breast and Cervical Cancer Screening Rates

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Subscribe

Related Content

Roles and Priorities Guiding Medicare Advantage Postacute Home Health Referrals

ByEmily A. Gadbois, PhD,Jennifer Bunker, MPH,Marguerite Daus, PhD, RN,Jamie M. Smith, PhD, RN,Emily Buss, MSN, RN,Christine D. Jones, MD, MS,Kali S. Thomas, PhD, MA

July 16th 2026

Reply to Letter Regarding “Preventive Dental Care and Overall Medical Expenditures”

ByHeather L. Taylor, MPH, LDH,Ann M. Holmes, PhD,Nir Menachemi, PhD, MPH,Justin Blackburn, PhD

July 10th 2026

Changes in Semaglutide Fills Following Expanded FDA and Medicare Policies

ByChristopher Scannell, MD, PhD,John A. Romley, PhD,Rebecca Myerson, PhD,Dana Goldman, PhD,Dima Mazen Qato, PharmD, PhD, MPH

July 9th 2026

Upper Payment Limit Implementation Risks for Patients, Pharmacies, and Providers

ByJulie A. Patterson, PharmD, PhD,Roswell A. Cole, PharmD, MPH,Jonathan D. Campbell, PhD, MS,John Michael O’Brien, PharmD, MPH

July 9th 2026

The New Oncology Blueprint: Integrating Clinical Intelligence for Sustainable Value

ByVivian T. E. Tar, PharmD, MBA

July 8th 2026

Verification of a Decision Analytic Model Assumption Using Real-world Practice Data: Implications for the Cost Effectiveness of Cyclo-oxygenase 2 Inhibitors (COX-2s)

Articles in this issue

Related Content

Roles and Priorities Guiding Medicare Advantage Postacute Home Health Referrals

Reply to Letter Regarding “Preventive Dental Care and Overall Medical Expenditures”

Changes in Semaglutide Fills Following Expanded FDA and Medicare Policies

Upper Payment Limit Implementation Risks for Patients, Pharmacies, and Providers

The New Oncology Blueprint: Integrating Clinical Intelligence for Sustainable Value

Trending on AJMC

NYC Legionnaires Disease Cluster Slows as Cooling Tower Remediation Continues

Medicaid Fraud Crackdown Intensifies, But Is It Solving the Right Problem?

MS Likely Unfolds Along a Continuum Years Before First Symptoms

FDA Approves Gedatolisib for HR+/HER2- Advanced Breast Cancer

CVI Range Assessment Validated as Reliable Measure of Functional Vision in Children

Access, Affordability, & Accountability: A New Era in Oncology Reimbursement

Verification of a Decision Analytic Model Assumption Using Real-world Practice Data: Implications for the Cost Effectiveness of Cyclo-oxygenase 2 Inhibitors (COX-2s)

Articles in this issue

Related Content

Roles and Priorities Guiding Medicare Advantage Postacute Home Health Referrals

Reply to Letter Regarding “Preventive Dental Care and Overall Medical Expenditures”

Changes in Semaglutide Fills Following Expanded FDA and Medicare Policies

Upper Payment Limit Implementation Risks for Patients, Pharmacies, and Providers

The New Oncology Blueprint: Integrating Clinical Intelligence for Sustainable Value

Trending on AJMC

NYC Legionnaires Disease Cluster Slows as Cooling Tower Remediation Continues

Medicaid Fraud Crackdown Intensifies, But Is It Solving the Right Problem?

MS Likely Unfolds Along a Continuum Years Before First Symptoms

FDA Approves Gedatolisib for HR+/HER2- Advanced Breast Cancer

CVI Range Assessment Validated as Reliable Measure of Functional Vision in Children